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ABSTRACT 
Myofibroblasts expressing -smooth muscle actin (-SMA) are the key cellular mediator of 
fibrosis. Fibrovascular epiretinal membranes from patients with proliferative diabetic 
retinopathy (PDR) are characterized by the accumulation of a large number of 
myofibroblasts. We explored the hypothesis that proliferating endothelial cells via 
endothelial-to-mesenchymal transition (EndoMT) and/or bone marrow-derived circulating 
fibrocytes contribute to the myofibroblast population present in PDR epiretinal membranes. 
Epiretinal membranes from 14 patients with PDR were studied by immunohistochemistry. 
All membranes contained neovessels expressing the endothelial cell marker CD31. CD31
+
 
endothelial cells co-expressed the fibroblast/myofibroblast markers fibroblast-specific 
protein-1 (FSP-1) and -SMA, indicative for the occurrence of endoMT. In the stroma, cells 
expressing FSP-1, -SMA, the leukocyte common antigen CD45, and the myelomonocytic 
marker CD11b were detected. Double labeling showed co-localization of CD45 with FSP-1 
and -SMA and co-localization of CD11b with -SMA and matrix metalloproteinase-9, 
demonstrating the presence of infiltrating fibrocytes. In addition, we investigated the 
phenotypic changes that take place in human retinal microvascular endothelial cells following 
exposure to transforming growth factor-β1 (TGF-β1), connective tissue growth factor 
(CTGF) and the proinflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-
 (TNF-). Retinal microvascular endothelial cells changed morphology upon cytokine 
exposure, lost the expression of endothelial cell markers (endothelial nitric oxide synthase 
and vascular endothelial-cadherin) and started to express mesenchymal markers (calponin, 
snail, transgelin and FSP-1). These results suggest that endothelial cells as well as circulating 
fibrocytes may differentiate into myofibroblasts in the diabetic eye and contribute to 
pathologic fibrosis in PDR. 
Key words: endothelial-to-mesenchymal transition (EndoMT); fibrocytes; myofibroblasts; 
proliferative diabetic retinopathy; endothelial cells; retina 
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1. Introduction 
Ischemia-induced pathologic growth of new blood vessels and expansion of 
extracellular matrix (ECM) in association with the outgrowth of fibrovascular epiretinal 
membranes at the vitreoretinal interface is the pathological hallmark in proliferative diabetic 
retinopathy (PDR), and often leads to catastrophic loss of vision due to vitreous hemorrhage 
and/or traction retinal detachment. Although the etiology of fibrotic disorders is quite diverse, 
and their pathogenesis is variable and dependent on the causative agent or initiating event, a 
common feature is the presence of large numbers of myofibroblasts and abnormal 
accumulation of ECM in the affected tissue(s). Myofibroblasts, the key cellular mediators of 
fibrosis, are contractile cells, characterized by the expression of -smooth muscle actin (-
SMA), and their presence is a marker of progressive fibrosis. They have the capacity to 
produce several ECM components including collagen resulting in fibrosis (Wynn, 2008). 
Such myofibroblasts, sometimes termed “activated fibroblasts”, are known to be present in 
the stromal compartment of most invasive human cancers, in areas of chronic inflammation, 
and in tissues undergoing the remodeling seen during wound healing (Wynn, 2008). In the 
epiretinal membranes from patients with PDR, inflammatory and fibrotic changes are 
characterized by the presence of inflammatory cells and -SMA-expressing myofibroblasts in 
the stromal compartment (Abu El-Asrar et al., 2006, 2007, 2013). 
 The origin(s) of myofibroblasts responsible for the exaggerated and uncontrolled 
production of ECM proteins in PDR epiretinal membranes has not been completely 
elucidated. Investigations of other fibrotic diseases suggest that the activated fibroblasts or 
myofibroblasts can probably derive from diverse origins, depending on the organ and on the 
pathology. Increasing evidence suggests that endothelial cells may undergo endothelial-to-
mesenchymal transition (EndoMT) or endothelial-to-myofibroblast transition under 
physiological, as well as pathological circumstances (Piera-Velasquez et al., 2011; He et al., 
2013). During EndoMT, endothelial cells lose their adhesion and apical-basal polarity to form 
highly invasive migratory, spindle-shaped elongated mesenchymal cells. More importantly, 
biochemical changes accompany these distinct changes in cell polarity and morphology, 
including the decreased expression of endothelial markers, such as CD31, vascular 
endothelial (VE)-cadherin, and endothelial nitric oxide synthase (eNOS) and the acquisition 
of mesenchymal markers, such as -SMA, fibroblast-specific protein-1 (FSP-1, also known 
as S100A4), calponin, and smooth muscle protein 22  (SM22) or transgelin (Piera-
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Velasquez et al., 2011; He et al., 2013). The cells undergoing transition may contain both 
endothelial and mesenchymal properties. For instance, Zeisberg et al. (2008) postulated that 
co-labeling of tissue with the endothelial marker CD31 and the mesenchymal markers -
SMA and FSP-1 reliably identifies myofibroblasts derived via EndoMT. It was demonstrated 
that transforming growth factor (TGF)-β1 treatment of mouse pancreatic microvascular 
endothelial cells and mouse lung endothelial cells induced EndoMT (Li et al., 2009; Zeisberg 
et al., 2007) and that snail, a zinc finger-containing transcription factor, mediates the actions 
of endogenous TGF-β1 signals that induce EndoMT (Piera-Velasquez et al., 2011; He et al., 
2013). In addition, the inflammatory cytokines interleukin-1β (IL-1β) or tumor necrosis 
factor- (TNF-) induced permanent transformation of human epithelioid dermal 
microvascular endothelial cells into myofibroblasts (Chaudhuri et al., 2007). Furthermore, co-
stimulation with IL-1β and TGF-β2 caused synergistic induction of EndoMT in human 
umbilical vein endothelial cells (Maleszewska et al., 2013). Recently, several studies 
provided strong evidence for the prominent participation of EndoMT in the generation of 
activated myofibroblasts in animal models of renal, cardiac, pulmonary, hepatic and intestinal 
fibrosis (Piera-Velasquez et al., 2011; He et al., 2013). Furthermore, EndoMT emerges as a 
possible source of cancer-associated fibroblasts (Zeisberg et al., 2007). In diabetic eyes, 
however, EndoMT has not yet been investigated. 
 In addition to EndoMT, several studies demonstrated that circulating bone marrow-
derived fibrocytes traffic to sites of tissue injury, differentiate into myofibroblasts, and 
contribute to collagen deposition and fibrosis (Keeley et al., 2011). Circulating fibrocytes 
express the hematopoietic stem cell marker CD34, the common leukocyte marker CD45 and 
the myeloid marker CD11b in conjunction with the fibroblast markers vimentin, collagen I, 
collagen III and fibronectin (Keeley et al., 2011). The expression of -SMA is a marker of 
differentiation of fibrocytes into myofibroblasts (Keeley et al., 2011).  
 In the present study, we explored the hypothesis that both EndoMT and bone marrow-
derived circulating fibrocytes contribute to the myofibroblast population present in the 
epiretinal membranes from patients with PDR. To identify fibrocytes that have undergone 
local differentiation into myofibroblasts, we performed double-labeling experiments to reveal 
cells co-expressing CD45/-SMA, CD45/FSP-1, and CD11b/-SMA. In addition, we 
performed CD31/FSP-1 and CD31/-SMA double-labeling to gain insights into possible 
EndoMT. Finally, we demonstrated that phenotypic changes take place in human retinal 
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microvascular endothelial cells (HRMEC) following exposure to TGF-β1, and the 
proinflammatory cytokines IL-1β and TNF-. In the stimulated cell cultures, retinal 
endothelial cells changed morphology, down-regulated endothelial cell markers and 
upregulated mesenchymal/myofibroblast markers. These findings corroborate the hypothesis 
that EndoMT can contribute to the fibrotic process occurring during PDR. 
 
2.  Materials and Methods 
2.1.  Epiretinal membrane specimens 
Epiretinal fibrovascular membranes were obtained from 14 patients with PDR during 
pars plana vitrectomy for the repair of tractional retinal detachment. The severity of retinal 
neovascular activity was graded clinically at the time of vitrectomy using previously 
published criteria (Aiello et al., 1994). Neovascularization was considered active if there 
were visible perfused new vessels on the retina or optic disc and present within tractional 
epiretinal membranes. Neovascularization was considered inactive (involuted) if only 
nonvascularized white fibrotic epiretinal membranes were present. Active PDR was present 
in 5 patients and inactive PDR was present in 9 patients. Membranes were fixed in 10% 
formalin solution and embedded in paraffin.  
The study was conducted according to the tenets of the Declaration of Helsinki. All 
patients were candidates for vitrectomy as a surgical procedure and signed a preoperative 
informed written consent approving the use of the excised epiretinal membranes for further 
analysis and clinical research. The study design and the protocol were approved by the 
Research Centre and Institutional Review Board of the College of Medicine, King Saud 
University. 
The sections from the control patients were obtained from patients treated at the 
University Hospital, University of Leuven, Belgium, in full compliance with tenets of the 
Declaration of Helsinki. We used archived material and patients gave written consent at 
admission for the use of the leftover material in studies. The Ethics Committee of the 
University Hospital, University of Leuven approved this consent procedure. 
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2.2.  Immunohistochemical staining 
For CD31 and -SMA detection, antigen retrieval was performed by boiling the 
sections in citrate based buffer (BOND Epitope Retrieval Solution 1, pH 5.9 – 6.1; Leica) for 
20 minutes. For FSP-1, CD45, CD11b and matrix metalloproteinase-9 (MMP-9) detection, 
antigen retrieval was performed by boiling the sections in Tris/EDTA buffer (BOND Epitope 
Retrieval Solution 2, pH 9; Leica) for 20 minutes. Subsequently, the sections were incubated 
with the monoclonal and polyclonal antibodies listed in Table 1. Optimal working 
concentrations and incubation times for the antibodies were determined earlier in pilot 
experiments. The sections were then incubated for 20 minutes with a post primary IgG linker 
followed by an alkaline phosphatase-conjugated polymer. The reaction product was 
visualized by incubation for 15 minutes with the Fast Red chromogen (BOND Polymer 
Refine Red Detection Kit; Leica), resulting in bright-red immunoreactive sites. The slides 
were then faintly counterstained with Mayer’s hematoxylin.  
To identify the phenotype of cells expressing FSP-1, -SMA and MMP-9, sequential 
double immunohistochemistry was performed. The stronger antigen retrieval (Tris/EDTA 
buffer) of the two single stainings was used when combining them in double staining. 
Therefore, only one antigen retrieval was performed per each double staining.  The sections 
were incubated with the first primary antibody (anti-CD31, anti-CD45 and anti-CD11b) and 
subsequently treated with peroxidase conjugated secondary antibody. Immunoreactive sites 
were visualized with 3,3’-diaminobenzidine tetrahydrochloride. Incubation of the second 
primary antibody (anti-FSP-1, anti--SMA and anti-MMP-9) was followed by treatment with 
alkaline phosphatase conjugated secondary antibody. Finally, the sections were treated with 
Fast Red colour solution. No counterstain was applied. 
Omission or substitution of the primary antibody with an irrelevant antibody from the 
same species and staining with chromogen alone were used as negative controls. Sections 
from patients with glioblastoma were used as positive controls to optimize the 
immunohistochemical staining methods.  
2.3.  Quantitation 
Immunoreactive blood vessels and cells were counted in five representative fields, 
using an eyepiece calibrated grid in combination with the 40x objective. These representative 
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fields were selected based on the presence of immunoreactive blood vessels and cells. With 
this magnification and calibration, immunoreactive blood vessels and cells present in an area 
of 0.33 x 0.22 mm² were counted. 
2.4.  Differentiation of retinal microvascular endothelial cells 
HRMEC were purchased from Cell Systems (Kirkland, WA) and cultured as 
described previously (Nawaz et al., 2013) in endothelial basal medium-2 (EBM-2) enriched 
with endothelial growth medium-2 MV Bulletkit, containing, besides fetal calf serum [FCS; 
final concentration 5% (v/v)], the growth factors epidermal growth factor, vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor and insulin-like growth 
factor 1 (Lonza, Verviers, Belgium). Three days after seeding in 6-well plates, differentiation 
of HRMEC was induced by addition of human recombinant IL-1, human recombinant TNF-
, human recombinant TGF-1 or human recombinant connective tissue growth factor 
(CTGF) (all from PeproTech, Rocky Hill, NJ) or combinations thereof and replacement of 
the growth-factor enriched endothelial cell growth medium by EBM-2 supplemented with 3% 
FCS. As a control to preserve the endothelial cell type, cultures in one well of each plate were 
contained in the endothelial cell growth medium supplemented with 10 ng/ml of VEGF. The 
differentiation medium was replaced every two days. After 4 days of stimulation, cell 
morphology and gene expression were investigated. Changes in cell morphology were 
documented using an Axiovert 200M inverted microscope, equipped with an EC Plan-
Neofluar 10× phase contrast objective (Carl Zeiss, Jena, Germany).  
2.5.  Quantitative measurement of gene expression 
Changes in gene expression 4 days after exposure of HRMEC to cytokines were 
studied using quantitative real-time PCR. Total RNA was extracted with the RNeasy kit 
(Qiagen, Hilden, Germany) according to the procedures of the manufacturer and quantified 
by UV absorption. RNA was converted into cDNA by reverse transcription using the high 
capacity cDNA Reverse Transcription kit from Applied Biosystems (Life Technologies, 
Gent, Belgium). Quantitative RT-PCR analysis was performed with the TaqMan gene 
expression master mix from Applied Biosystems and primers and probes, supplied as 
PrimeTime qPCR assays, by Integrated DNA Technologies (Table 2) on 50 ng of cDNA in 
an Applied Biosystems 7500 fast real-time PCR system. The relative abundance of transcripts 
was determined by the 2
-Ct
 method. Ct values were calculated using 18S ribosomal RNA 
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as a reference (assay no. Hs.PT.45.122532.g). Upregulation or down-regulation of a gene of 
interest was calculated relative to the control culture in which the full endothelial growth 
medium was replaced by EBM-2 + 3% FCS without addition of cytokine(s). At least four 
independent experiments were performed in which each condition was tested in duplicate. 
2.6.  Western blot analysis 
HRMEC were maintained in complete serum free media (Cat. No. SF-4Z0-500, Cell 
Systems) supplemented with Rocket fuel (Cat No. SF-4ZO-500, Cell systems), culture boost 
(Cat. No. 4CB-500, Cell Systems) and antibiotics (Cat. No. 4ZO-643, Cell Systems) at 37°C 
in a humidified atmosphere with 5% CO2. When HRMEC cells reached 80% confluency, 
cultures were starved overnight in a minimal medium containing antibiotics, 0.5% rocket fuel 
and without culture boost. Following starvation, HRMEC cells were left untreated or treated 
in minimal starvation medium either with TNF-α, IL-1β, TGF-β1, CTGF (ab50044, Abcam,  
Cambridge, CB4 0FL,UK) or with a cocktail of cytokines containing either TNF-α plus IL-1β 
plus TGF-β1 or TNF-α plus IL-1β plus CTGF. All conditions were tested in triplicate. After 
every 48 hours, the media of all the groups with respective cytokines were replaced. Cells 
were harvested after 6 days for analysing the expression pattern of various proteins involved 
in EndoMT. HRMEC cells were lysed with RIPA buffer [50 mM Tris/HCl, pH 7.5, 150 mM 
NaCl, 1% (v/v) nonidet P40 (NP40), 0.5% sodium deoxycholate, 0.1% SDS and protease 
inhibitor “Complete without EDTA” (Roche, Mannheim, Germany)]. Whole cell extracts 
were centrifuged at 12,000 ×g for 10 minutes at 4°C. The supernatants were collected and 
protein concentrations were measured using the DC protein assay kit (Bio-Rad Laboratories, 
Hercules, CA). Whole cell extracts containing 50 μg of protein were separated on 8–12% 
SDS-polyacrylamide gels and were transferred onto nitrocellulose membranes. Blocking was 
performed with 5% skim milk in Tris buffered saline (TBS-T) (50 mM Tris-Cl, pH 7.6, 150 
mM NaCl, 0.05% Tween 20) for 1 hour. For the detection of eNOS, VE-cadherin and FSP-1, 
the membranes were incubated overnight at 4°C with the respective primary antibody. The 
antibodies used were goat polyclonal anti-eNOS (1:1000, Cat. no. AF950, R&D Systems, 
Minneapolis, MN), mouse monoclonal anti-VE-cadherin (1 : 500, Cat no. SC-9989, Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA), and rabbit polyclonal anti-FSP-1 (1:500, Cat no. 
SC-292281, Santa Cruz Biotechnology, Inc.,). After overnight incubation with primary 
antibodies, the membranes were washed four times with TBS-T (5 minutes each). Then the 
membranes were incubated with respective secondary antibodies at room temperature for 
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1 hour. Anti-goat horseradish peroxidase (HRP)-conjugated antibody (1 : 3000, SC-2768), 
anti-mouse HRP-conjugated antibody (1 : 3000, SC-2005), and anti-rabbit HRP-conjugated 
antibody (1 : 3000, SC-2004) were purchased from Santa Cruz Biotechnology, Inc.. After 
incubations with secondary antibodies, membranes were washed four times with TBS-T 
(5 minutes each) and the intensity of bands was visualized on a high-performance 
chemiluminescence machine (G: Box Chemi-XX8 from Syngene, Synoptic Ltd. Cambridge, 
UK) by using enhanced chemiluminescence plus Luminol (SC-2048, Santa Cruz). The 
membranes that were used to probe e-NOS, VE-cadherin and FSP-1 were re-probed for β-
actin (mouse monoclonal anti-β-actin antibody (C4), 1:2000 SC-47778, Santa Cruz) to verify 
equal loading. Band intensities were quantified using image software GeneTools (Syngene by 
Synoptic Ltd. Cambridge, UK) and ratios for marker expression over -actin expression were 
calculated. Statistical analysis was done on the results obtained from three independent 
experiments and each experiment was in triplicate. 
2.7.  Statistical Analysis 
Data are presented as the mean ± standard deviation (SD), unless otherwise indicated 
(Fig. 6). The non-parametric Mann-Whitney U test was used to compare means from two 
independent groups. Pearson correlation coefficients were computed to investigate 
correlations between variables. A p-value less than 0.05 indicated statistical significance. 
SPSS version 19.0 (IBM Inc., Chicago, IL) and program 3S from the BMDP 2007 Statistical 
Package were used for the statistical analyses. 
 
3.  Results 
3.1. Neovascularization and expression of mesenchymal markers in epiretinal membranes 
from patients with PDR 
 The level of vascularization in epiretinal membranes was determined by 
immunodetection of the endothelial cell marker CD31. No staining was observed in the 
negative control slides, in which an irrelevant primary antibody was used (Fig. 1A). 
However, using anti-CD31, all membranes showed blood vessels positive for this endothelial 
cell marker (Fig. 1B), with a mean number of 43±45 (range, 12-125). Fibrotic tissue is often 
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infiltrated by mesenchymal cells (expressing -SMA and FSP-1) secreting new ECM. Strong 
immunoreactivity for FSP-1 was present in all membranes and was observed in the cytoplasm 
of stromal cells (Fig. 1C) and vascular endothelial cells (Fig. 1D, E). The number of FSP-1 
immunoreactive stromal cells ranged from 10 to 195, with a mean number of 75±64. The 
number of FSP-1 immunoreactive blood vessels ranged from 1 to 30, with a mean number of 
10±10. Similarly, cytoplasmic immunoreactivity for -SMA was noted in stromal cells and 
vascular endothelial cells (Fig. 1F, G).  
The mean number of blood vessels expressing CD31, was significantly higher in 
membranes from patients with active PDR (98±26) than in membranes from patients with 
inactive PDR (13±8) (p=0.001). In addition, the mean number of stromal cells expressing 
FSP-1 was significantly higher in membranes from patients with active PDR (139±43) than 
in membranes from patients with inactive PDR (39±41) (p=0.004). However, the difference 
between the mean numbers of blood vessels expressing FSP-1 in membranes from patients 
with active PDR (14±7) and in membranes from patients with inactive PDR (8±10) was not 
significant (p=0.112). A significant positive correlation was detected between the numbers of 
blood vessels expressing CD31 and the numbers of stromal cells expressing FSP-1 (r=0.77, 
p=0.001). On the other hand, the correlation between the numbers of blood vessels expressing 
CD31 and the numbers of blood vessels expressing FSP-1 was not significant (r=0.47, 
p=0.093). 
3.2.  CD45
+
/FSP-1
+
 and CD45
+
/-SMA+ double-positive cells in epiretinal membranes from 
patients with PDR 
 To verify whether bone marrow-derived circulating fibrocytes contribute to the 
myofibroblast population present in the epiretinal membranes from patients with PDR, we 
performed immunohistochemistry with anti-CD45, anti-FSP-1 and anti--SMA antibodies. 
All membranes showed stromal cells expressing the leukocyte common antigen CD45, in 
their plasma membrane (Fig. 2A). The number of CD45 immunoreactive stromal cells ranged 
from 5 to 230, with a mean number of 85±99. The mean numbers of stromal cells expressing 
CD45, were significantly higher in membranes from patients with active PDR (177±113) 
than in membranes from patients with inactive PDR (34±38) (p=0.004). A significant positive 
correlation was detected between the number of blood vessels expressing CD31 and the 
number of stromal cells expressing CD45 (r=0.81, p=0.001). To identify fibrocytes that had 
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undergone local differentiation into mesenchymal cells, double-labeling experiments were 
performed. CD45
+
 cells (brown) co-expressing FSP-1 (red) (Fig. 2B) and -SMA (red) (Fig. 
2C, D) were detected. 
3.3.  CD11b
+
/-SMA+ and CD11b+/MMP-9+ double-positive cells in epiretinal membranes 
from patients with PDR 
 Next we investigated whether fibrocytes are recruited into the stroma of diabetic 
epiretinal membranes and in situ differentiate into myofibroblasts. Immunoreactivity for the 
myeloid marker CD11b, present on fibrocytes, was identified in all membranes and was 
noted in stromal cells (Fig. 3A) and vascular endothelial cells (Fig. 3B). The number of 
immunoreactive stromal cells ranged from 10 to 160, with a mean number of 58±43. The 
number of immunoreactive blood vessels ranged from 4 to 65, with a mean number of 23±17. 
The mean number of stromal cells expressing CD11b, was significantly higher in membranes 
from patients with active PDR (87±43) than in membranes from patients with inactive PDR 
(42±35) (p=0.029). Similarly, the mean number of blood vessels expressing CD11b, was 
significantly higher in membranes from patients with active PDR (37±16) than in membranes 
from patients with inactive PDR (12±12) (p=0.012). A significant positive correlation was 
detected between the numbers of blood vessels expressing CD31 and either the numbers of 
stromal cells expressing CD11b (r=0.55, p=0.048) or blood vessels expressing CD11b 
(r=0.67, p=0.009). Double immunohistochemistry indicated that CD11b-positive cells 
(brown) co-expressed -SMA (red) (Fig. 3C, D) and MMP-9 (red) (Fig. 3E). 
3.4.  CD31
+
/FSP-1
+
 and CD31
+
/-SMA+ double-positive cells in epiretinal membranes from 
patients with PDR 
Double immunohistochemistry revealed that some endothelial cells expressing the 
endothelial cell marker CD31 (brown) co-expressed FSP-1 (red) (Fig. 4A, B) and -SMA 
(red) (Fig. 4C, D). These findings suggest that endothelial cells are undergoing phenotypic 
conversion and are beginning to acquire fibroblast/myofibroblast markers.  
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3.5.  Cultured retinal microvascular endothelial cells can acquire characteristics of 
myofibroblasts upon appropriate cytokine treatment 
To verify the hypothesis that EndoMT indeed occurs in epiretinal membranes of 
diabetic patients, we tested whether cultured HRMEC could also be reprogrammed. We 
stimulated HRMEC with 10 ng/ml TGF-1, 30 ng/ml TNF-, 10 ng/ml IL-1 or 0.5 μg/ml 
CTGF alone or combinations thereof and concurrently removed the endothelial growth 
factors from the culture medium (see Materials and Methods). We compared cell cultures 
maintained for 4 days in those conditions to cultures kept in the presence of full endothelial 
growth medium supplemented with 10 ng/ml of VEGF. Figure 5 shows that the deprived 
cells changed their morphology drastically in the presence of TNF- plus IL-1, regardless of 
the presence or absence of TGF-1. Reduced cell-to-cell contacts were observed and the cells 
resembled myofibroblasts with an irregular, elongated shape. On the other hand, CTGF did 
not change the morphology of the cells (data not shown). We isolated RNA from the cell 
cultures and analysed the modulation of gene expression in response to the altered culture 
conditions (Fig. 6). We first studied the mRNA expression levels of the endothelial cell 
markers CD31, VE-cadherin and eNOS. Treatment with TNF- plus IL-1 or TNF- plus 
IL-1 plus TGF-1 resulted in a significant downregulation of VE-cadherin and eNOS gene 
expression, whereas no change in CD31 expression was detected. Concurrently, the 
myofibroblast-like cells upregulated transcription of the mesenchymal genes snail, transgelin 
and calponin in response to combined stimulation (n=4, Fig. 6), or in response to IL-1 alone 
(n=2, data not shown). The fact that CD31 expression levels remained unchanged suggests 
that the transition to myofibroblasts is not fully complete yet and that we obtained an 
intermediate differentiation status, similar to the phenotype of cells detected by 
immunohistochemistry (CD31
+
/-SMA+ and CD31+/FSP-1+) in the pathologic membranes.  
The observed changes in mRNA levels in the cultured HRMEC were confirmed by 
Western blot analysis (Fig. 7). On day 6, Western blot analysis revealed significant 
dowregulation of eNOS protein in response to TNF-IL-1TGF-1 or TNF- plus IL-1 
plus TGF-1 treatment. Similarly, IL-1TGF-1 or TNF- plus IL-1 plus TGF-1 
treatment resulted in a significant downregulation of VE-cadherin. Treatment with TNF-, 
IL-1, TGF-1 or TNF- plus IL-1 plus TGF-1 resulted in a significant upregulation of 
FSP-1 protein levels. Treatment of HRMEC with CTGF alone did not affect the expression of 
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eNOS, VE-cadherin and FSP-1 as compared to untreated control (data not shown). In 
conclusion, our data support the occurrence of EndoMT in cultures of HRMEC. 
    
4.  Discussion 
 Here, we demonstrated for the first time that endothelial cells in epiretinal 
fibrovascular membranes from patients with PDR contribute to the emergence of 
fibroblasts/myofibroblasts via the process of EndoMT. We report that some endothelial cells 
expressing CD31 co-express the fibroblast marker FSP-1 and the myofibroblast marker -
SMA. The presence of CD31
+/
FSP-1
+
 and CD31
+
/-SMA+ cells indicates an intermediate 
stage of EndoMT (Zeisberg et al., 2007, 2008). Our observations suggest that EndoMT plays 
a role in creating fibroblasts and myofibroblasts responsible for fibrosis and progression of 
PDR. These findings also suggest that EndoMT contributes to the loss of endothelial cells in 
PDR epiretinal membranes and the spontaneous regression of new blood vessels in patients 
with end-stage PDR. These findings raise the possibility that inhibiting EndoMT may be an 
effective therapy for delaying the progression of fibrosis associated with PDR. 
 Our in vivo findings are consistent with previous in vitro data demonstrating that high 
glucose treatment induced EndoMT in human aortic endothelial cells and human umbilical 
vein endothelial cells (Tang et al., 2010, 2013; Widyantoro et al., 2010). High glucose 
treatment reduced VE-cadherin levels and induced the expression of FSP-1 protein, and co-
localization of both CD31 and FSP-1 (Tang et al., 2010, 2013; Widyantoro et al., 2010). 
EndoMT was also induced in a mouse pancreatic microvascular endothelial cell line in the 
presence of advanced glycation end products(Li et al., 2010). In our in vitro experiments we 
were also able to demonstrate differentiation of retinal microvascular endothelial cells into 
spindle-shaped cells displaying downregulation of the endothelial cell markers, such as eNOS 
and VE-cadherin and upregulation of the mesenchymal markers calponin, snail, transgelin 
and FSP-1. In Fig. 6 CD31 expression was not yet downregulated on day 4, but several 
authors report co-expression of CD31 with mesenchymal markers, before CD31 expression is 
downregulated at a later stage of EndoMT (Zeisberg et al., 2007; Tang et al., 2010). Besides, 
also in the immunohistochemical analysis of the diabetic epiretinal membranes (Fig. 4) co-
expression of CD31 with -SMA and FSP-1 was detected. In view of the above mentioned 
literature, we also tested exposure of the endothelial cells to high glucose levels. However, 
14 
 
we did not observe a clear effect on the cell cultures, neither at a morphological level, nor in 
gene expression (data not shown). This discrepancy might be explained by the fact that 
HRMEC used in our study respond differently compared to other types of endothelial cells. 
  In addition, on the basis of animal experiments it has previously been suggested that 
EndoMT plays an important role in the progression of diabetes-induced renal fibrosis 
(Zeisberg et al., 2008; Li et al., 2009) and cardiac fibrosis (Tang et al., 2013; Widyantoro et 
al., 2010). In a mouse model of streptozotocin (STZ)-induced diabetic nephropathy, Zeisberg 
et al. (2008) demonstrated that a considerable proportion of all FSP-1
+
 fibroblasts and -
SMA
+
 myofibroblasts co-expressed the endothelial marker CD31. Li et al. 2009) confirmed 
that EndoMT occurs and contributes to the generation of myofibroblasts in early STZ-
induced diabetic nephropathy in mice. These findings strongly indicate the existence of 
endothelial-origin fibroblasts/myofibroblasts in diabetic nephropathy and suggest that 
EndoMT may be a pathway leading to interstitial fibrosis in diabetic nephropathy. Similarly, 
recent studies demonstrated that STZ-induced cardiac fibrosis is associated with the 
emergence of fibroblasts from endothelial cells. Labeling experiments showed that CD31-
labeled endothelial cells co-expressed FSP-1 (Tang et al., 2013; Widyantoro et al., 2010).  
 In the present study, we described the in situ localization of FSP-1 in leukocytes, 
expressing the leukocyte common antigen CD45, as well as in endothelial cells in epiretinal 
membranes from patients with PDR. In accordance with our results, previous studies reported 
that FSP-1
+
cells are also increased in experimental models of renal fibrosis (He et al., 2013; 
Zeisberg et al., 2008), cardiac fibrosis (Tang et al., 2013; Widyantoro et al., 2010), liver 
diseases (Österreicher et al., 2011), cancer (Zeisberg et al., 2007) and vein grafts (Cheng et 
al., 2012). In a rat model of renal peritubular inflammation, FSP-1
+
 cells consistently co-
expressed CD45. In addition, FSP-1 stained endothelial cells in the mouse model of renal 
peritubular inflammation (Le et al., 2005). In liver diseases, FSP-1
+
 cells co-expressed 
markers of the myeloid-monocytic lineage (macrophages and/or dendritic cells) (Österreicher 
et al., 2011). In vein grafts, FSP-1
+
 cells also stained positively for CD45 and CD11b 
(Österreicher et al., 2011). These findings indicate that FSP-1
+
 stromal cells in PDR epiretinal 
membranes are of hematopoietic origin. 
 In fibrovascular epiretinal membranes from patients with PDR, we demonstrated 
accumulation of mononuclear cells of monocyte/macrophage lineage expressing CD45 and 
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CD11b. A subset of these cells co-expressed FSP-1 and -SMA, thus exhibiting 
mesenchymal cell characteristics attributed to fibrocytes (Keeley et al., 2011). We concluded 
that circulating mesenchymal precursors of a monocyte/macrophage lineage, including 
fibrocytes, are another source of myofibroblasts and thus contribute to fibrosis in PDR. TGF-
β1 plays an important role during the transdifferentiation of monocytes/macrophages 
expressing CD11b into cells expressing the myofibroblast markers -SMA and calponin 
(Ninomiya et al., 2006). The chemokine receptor-ligand pair CXCR4-stromal cell-derived 
factor-1 (SDF-1/CXCL12) has been shown to play a particularly important role in the homing 
of circulating fibrocytes to sites of fibrosis (Keeley et al., 2011). In previous studies, we 
demonstrated expression of the CXCL12/CXCR4 chemokine axis in PDR epiretinal 
membranes (Abu El-Asrar et al., 2010, 2011). 
 New blood vessels in PDR epiretinal membranes are derived from sprouting from 
preexisting endothelial cells (angiogenesis) and circulating bone marrow-derived endothelial 
precursor cells (vasculogenesis) (Ninomiya et al., 2006; Abu El-Asrar et al., 2010, 2011). In 
the present study, we demonstrated that vascular endothelial cells in PDR epiretinal 
membranes expressed the myelomonocytic marker CD11b. These findings suggest that bone 
marrow-derived CD11b
+ 
myelomonocytic cells play an important role in PDR 
vasculogenesis. In addition, CD11b
+ 
cells co-expressed MMP-9. This observation 
corroborates several recent studies reporting that CD11b
+
 cells have multiple tumor-
promoting effects. They show high proangiogenic activity as they actively secrete MMP-9, 
which facilitates endothelial cell migration and liberates matrix-bound growth factors, such as 
VEGF. In addition, CD11b
+
 cells directly differentiate and incorporate in the vascular 
endothelium, promoting tumor vascularization and tumor progression (Yang et al., 2004; 
Laurent et al., 2011; Ahn and Brown, 2008). Furthermore, several studies demonstrated an 
essential role for MMP-9 in mediating myofibroblast invasion (Turner et al., 2007) and that 
fibrocytes expressed high levels of MMP-9 and their migration was MMP-dependent (Sato et 
al., 2009). In addition, circulating monocytic cells were recently shown to interact with 
endothelial cells of pulmonary capillaries in a mouse model of acute lung capillary injury and 
repair. Circulating monocytic cells were shown to express VEGF, to move into close 
apposition to adjacent capillary endothelium and to fuse to endothelial plasmalemmal 
membranes and to the endothelial cells of regenerating capillaries after injury. The expression 
of CXCR4 by the circulating monocytic cells, and of CXCL12 by adjacent endothelial cells, 
demonstrates a mechanism for retention of these cells at the capillary surface. Myeloid VEGF 
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receptor-2
+
 CD11b
+
 precursors are identified within the circulating monocytic cell population 
(Jones and Capen, 2012, 2014). In previous studies we demonstrated the presence of 
endothelial cells expressing CXCL12 and stromal cells expressing CXCR4 and VEGF 
receptor-2 in fibrovascular epiretinal membranes from patients with PDR (Abu El-Asrar et 
al., 2010, 2011). 
  As both pro-inflammatory and pro-fibrotic mechanisms contribute to the progression 
of PDR (Abu El-Asrar, et al., 2006, 2007, 2013), we hypothesized that they also interact in 
the regulation of EndoMT. Therefore, we investigated the pro-EndoMT effect of TGF-β1 in 
the context of inflammatory TNF- and IL-1β co-stimulation. Indeed, co-stimulation with the 
pro-inflammatory cytokines TNF- and IL-1β and the pro-fibrotic cytokine TGF-β1 caused 
synergistic induction of the mesenchymal marker transgelin, and possibly calponin, in 
HRMEC. However, no additive/synergistic effect of TGF-β1 on the combination of TNF- 
plus IL-1β was observed in downregulating the endothelial markers eNOS and VE-cadherin 
(Fig. 6). Our findings suggest that the ocular microenvironment in PDR at the verge between 
inflammation and tissue remodeling can strongly promote the process of EndoMT. 
 In conclusion, these findings suggest that EndoMT and circulating bone marrow-
derived fibrocytes contribute to the accumulation of myofibroblasts and the development and 
progression of fibrosis in PDR. A greater understanding of the molecular mechanisms 
involved in the EndoMT process and modulating the activity of fibrocytes and the subsequent 
pharmacological blockade of these pathways may represent a novel therapeutic approach to 
retard the progression of fibrosis associated with PDR. 
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Table 1. Monoclonal and polyclonal antibodies used in this study 
Primary Antibody Dilution Incubation Time Sources* 
 Anti-CD31 
   (Clone JC70A) (mc) 
Undiluted 60 minutes Dako 
 Anti--smooth muscle actin 
   (Clone 1A4) (mc) 
1/200 60 minutes Dako 
 Anti-CD45 
   (Clones 2B11 + PD7/26) (mc) 
1/50 60 minutes Dako 
 Anti-S100A4 
   (Cat no. ab113527) (pc) 
1/50 60 minutes Abcam 
 Anti-MMP-9 
   (Clone REGA-2D9) (mc) 
1/50 60 minutes 
(Paemen et 
al., 1995) 
 Anti-CD11b 
   (Cat no. ab75476) (pc) 
1/100 60 minutes Abcam 
 *Location of manufacturers: Dako, Glostrup, Denmark; Abcam, Cambridge, UK. 
   mc = monoclonal; pc = polyclonal   
 
 
 
 
1 
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Table 2. Primers and probes for the study of endothelial-to-mesenchymal transition 
Gene PrimeTime qPCR Primers (5’→ 3’) Probe (5’→ 3’) 
    
CD31 Hs.PT.53a.19487865 ATTGCTCTGGTCACTTCTCC 
CAGGCCCCATTGTTCCC 
/HEX/TGTGGCGCT/ZEN/GGTCAGGTAATGG/3IABkFQ/ 
VE-cadherin Hs.PT.56a.4732035 TGCCCACATATTCTCCTTTGAG 
GAACCAGATGCACATTGATGAAG 
/6-FAM/TGAGTCGCA/ZEN/AGAATGCCAAGTACCT/3IABkFQ/ 
eNOS Hs.PT.56a.21447620 ACGATGGTGACTTTGGCTA 
TGGAGGATGTGGCTGTCT 
/6-FAM/CAGTGGAAA/ZEN/TCAACGTGGCCGTG/3IABkFQ/ 
Transgelin Hs.PT.56a.2301360.g ATCATTCTTGGTCACTGCCA 
CATGTTCCAGACTGTTGACCT 
/6-FAM/CTGCTGCCA/ZEN/TGTCTTTGCCTTCA/3IABkFQ/ 
Snail Hs.PT.56a.2984401 GCACTGGTACTTCTTGACATCT 
GGCTGCTACAAGGCCAT 
/HEX/TTCGCTGAC/ZEN/CGCTCCAACCT/3IABkFQ/ 
Calponin Hs.PT.56a.38799164 CATGAAGTTGTTGCCGATGC 
TCAGCCGAGGTTAAGAACAAG 
/HEX/CCTCGATCC/ZEN/ACTCTCTCAGCTCCT/3IABkFQ/ 
18S Hs.PT.45.122532.g ATCGCTCCACCAACTAAGAAC 
ACGGACAGGATTGACAGATTG 
/6-FAM/ACCACCCAC/ZEN/GGAATCGAGAAAGAG/3IABkFQ/ 
*All primer/probe sets were supplied as PrimeTime qPCR assays by Integrated DNA Technologies (Haasrode, Belgium) 
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Legends to Figures 
Figure 1. Immunodetection of endothelial and mesenchymal markers in proliferative diabetic 
retinopathy epiretinal membranes. A specific labeling was excluded by following 
the full staining procedure using an irrelevant primary antibody (A, negative 
control slide) (scale bar, 10 μm). Immunohistochemical staining for CD31 showing 
blood vessels positive for this endothelial cell marker (B) (scale bar, 10 μm). 
Immunohistochemical detection of fibroblast specific protein-1 (FSP-1), in stromal 
cells (C) (scale bar, 10 μm) and cells lining blood vessels (D and E) (scale bar, 10 
μm and 8 μm, respectively). Immunohistochemical staining for -smooth muscle 
actin (-SMA) showing immunoreactivity in myofibroblasts (F) (scale bar, 10 μm) 
and in the vascular endothelium (G) (scale bar, 8 μm). 
Figure 2. Characterization of CD45
+
 stromal cells in proliferative diabetic retinopathy 
epiretinal membranes. Numerous CD45
+
 stromal cells were detected (A) (scale bar, 
10 μm). Double immunohistochemistry for CD45 (brown) and FSP-1 (red) 
showing co-expression in stromal cells (arrows) (B) (scale bar, 10 μm). Double 
immunohistochemistry for CD45 (brown) and -SMA (red) demonstrating co-
expression in stromal cells (arrows) (C and D) (scale bar, 10 μm and 8 μm, 
respectively).  
Figure 3. Identification of CD11b
+
 cells in proliferative diabetic retinopathy epiretinal 
membranes. After incubation of biopsies with antibodies against CD11b , stromal 
cells (A) and blood vessels (B) (scale bar, 10 μm) stained positive. Double 
immunohistochemistry for CD11b (brown) and -SMA (red) (C and D, (scale bar, 
10 μm and 8 μm, respectively) demonstrated cells co-expressing CD11b and -
SMA in the vascular endothelium (arrows) and in the stroma (arrow heads). 
Double immunohistochemistry for CD11b (brown) and matrix metalloproteinase-9 
(MMP-9) (red) identified stromal cells co-expressing CD11b and MMP-9 (arrows) 
(E) (scale bar, 8 μm). 
Figure 4. Evidence for the occurrence of endoMT in proliferative diabetic retinopathy 
epiretinal membranes. Immunohistochemical analysis for co-expression (arrows) 
of the endothelial marker CD31 (brown) and either FSP-1 (red) (A, B) (scale bar, 8 
μm) or -SMA (red) (C, D) (scale bar, 8 μm).  
Figure 5. Cytokine-induced morphologic changes in retinal microvascular endothelial cells. 
HRMEC were cultured in the presence of 10 ng/ml IL-1 plus 30 ng/ml TNF- or 
10 ng/ml IL-1 plus 30 ng/ml TNF- plus 10 ng/ml TGF-1 as described in the 
materials and methods section. The medium of the control cultures (Ctrl) was 
replaced by EBM-2 + 3%FCS without addition of cytokine(s). In alternative control 
cultures (VEGF), the endothelial cell type was preserved in the presence of 10 
ng/ml VEGF and full endothelial cell growth medium. Representative pictures were 
made using a 10x phase contrast objective (scale bar 200 µm). 
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Figure 6. Differential endothelial and mesenchymal gene regulation in retinal microvascular 
endothelial cells (HRMEC) by cytokines and cytokine mixtures. 
HRMEC were stimulated to undergo EndoMT as described in the materials and 
methods section with 10 ng/ml TGF-1, 10 ng/ml IL-1 plus 30 ng/ml TNF- or 
10 ng/ml IL-1 plus 30 ng/ml TNF- plus 10 ng/ml TGF-1. Alternatively, the 
endothelial cell type was preserved in the continuous presence of 10 ng/ml vascular 
endothelial growth factor (VEGF). Changes in expression of genes related to an 
endothelial (endothelial nitric oxide synthase (eNOS), vascular endothelial (VE)-
cadherin, CD31) or mesenchymal (calponin, snail, transgelin) cell type were 
detected by quantitative RT-PCR. Upregulation or down-regulation of a gene of 
interest was calculated relative to the control culture (Ctrl) in which the full 
endothelial growth medium was replaced by EBM-2 + 3%FCS without addition of 
cytokine(s). Results shown are mean values ± SEM from at least 4 independent 
experiments performed in duplicate. * or $ indicate a statistically significant 
upregulation or downregulation compared to the Ctrl culture, respectively (p<0.05 
Mann Whitney U test). # indicates a statistically significant difference between two 
cytokine-stimulated groups (p<0.05 Mann Whitney U test). 
Figure 7. Differential endothelial and mesenchymal marker expression in cytokine-stimulated 
human retinal microvascular endothelial cells (HRMEC). HRMEC were left 
untreated or were treated with either TNF- (30 ng/ml), IL-1 (10 ng/ml), TGF-
1(10ng/ml), or with a combination of cytokines containing TNF- (30 ng/ml) 
plus IL-1 (10 ng/ml) plus TGF-1 (10 ng/ml) for 6 days. The levels of expression 
of various markers for endothelial-to-mesenchymal transition were compared by 
Western blot analysis. Whole cell lysates were separated by SDS-PAGE (50 µg 
protein/lane), blotted and markers of interest were detected by specific antibodies. 
Equal loading was verified by reprobing the membranes for -actin content. 
Western blots are representative of three different experiments, each is performed 
in triplicate. 
 *The difference between the two means was statistically significant at 5% level of 
significance. 
 FSP-1 = Fibroblast-specific protein-1 
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